{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:55:24Z","timestamp":1774634124110,"version":"3.50.1"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Psoriasis, a chronic skin condition, characterized by scaly erythematous plaques, is prevalent in around 2% of the population. Around 25% of psoriasis patients have psoriatic arthritis (PsA), an inflammatory musculoskeletal disease that often leads to progressive joint damage and disability. Psoriatic diseases (PsD) encompassing psoriasis and PsA, are often associated with pathophysiologically related conditions like uveitis and inflammatory bowel disease as well as comorbidities such as cardiovascular disease. Due to the heterogeneous nature of PsD, diagnosis and treatment is a challenge. Biomarkers can objectively measure variables, such as disease state, disease progress, and treatment outcomes, thus offering the possibility for better management of disease. This review focuses on some of the biomarker research that was carried out in PsD in the past year.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Diverse biomarker types ranging from SNPs, mRNA, proteins, metabolites and immune cell profiles have been categorized as per the Biomarkers, EndpointS and other Tools (BEST) resource developed by the FDA\/NIH. Some of the latest research has focused on multiomic assays and these along with advanced bioinformatic tools can help in better disease management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Recent developments in PsA biomarker research show promise in identifying markers that can help in diagnosis, assess disease activity and predict treatment response. However, most studies are in the early discovery and verification state. Large-scale studies to replicate findings and develop and validate predictive algorithms are required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001086","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:00:09Z","timestamp":1740999609000},"page":"225-232","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Biomarker discovery in psoriatic disease"],"prefix":"10.1097","volume":"37","author":[{"given":"Darshini","family":"Ganatra","sequence":"first","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Research Program, Schroeder Arthritis Institute, Krembil Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Research Program, Schroeder Arthritis Institute, Krembil Research Institute"},{"name":"Division of Rheumatology, Department of Medicine"},{"name":"Institute of Medical Science"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41582-020-0362-2","article-title":"Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities","volume":"16","author":"Davis","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/apm.12934","article-title":"Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases","volume":"127","author":"Litman","year":"2019","journal-title":"APMIS"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3892\/br.2023.1667","article-title":"Comprehensive analysis of mitochondrial DNA variants, mitochondrial DNA copy number and oxidative damage in psoriatic arthritis","volume":"19","author":"Alwehaidah","year":"2023","journal-title":"Biomed Rep"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.42942","article-title":"Genetically proxied interleukin-13 inhibition is associated with risk of psoriatic disease: a Mendelian randomization study","volume":"76","author":"Zhao","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"1417564","DOI":"10.3389\/fimmu.2024.1417564","article-title":"Plasma proteins and psoriatic arthritis: a proteome-wide Mendelian randomization study","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Immunol"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"9927964","DOI":"10.1155\/2024\/9927964","article-title":"Circulating immune landscape profiling in psoriasis vulgaris and psoriatic arthritis by mass cytometry","volume":"2024","author":"Sang","year":"2024","journal-title":"J Immunol Res"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3389\/fimmu.2019.01525","article-title":"The role of epigenetics in autoimmune\/inflammatory disease","volume":"10","author":"Surace","year":"2019","journal-title":"Front Immunol"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/art.42654","article-title":"Prediction of psoriatic arthritis in patients with psoriasis using DNA methylation profiles","volume":"75","author":"Cruz-Correa","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2147\/CCID.S437936","article-title":"Association of complete blood cell count-derived inflammatory biomarkers with psoriasis and mortality","volume":"16","author":"Zhao","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"10371","DOI":"10.1038\/s41598-023-37412-6","article-title":"Association of inflammatory biomarkers and disease activity with subclinical myocardial dysfunction in psoriatic arthritis","volume":"13","author":"Pletikosic","year":"2023","journal-title":"Sci Rep"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"14970","DOI":"10.3390\/ijms241914970","article-title":"Dickkopf-related protein 1 (DKK-1) as a possible link between bone erosions and increased carotid intima-media thickness in psoriatic arthritis: an ultrasound study","volume":"24","author":"Bita","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00296-023-05391-6","article-title":"Clinical significance of possible HLA biomarkers in axial spondyloarthritis beyond HLA-B27 positivity","volume":"43","author":"Segota","year":"2023","journal-title":"Rheumatol Int"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"1245876","DOI":"10.3389\/fimmu.2023.1245876","article-title":"DNA methylation patterns in CD4(+) T-cells separate psoriasis patients from healthy controls, and skin psoriasis from psoriatic arthritis","volume":"14","author":"Natoli","year":"2023","journal-title":"Front Immunol"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/1354750X.2024.2319297","article-title":"Circulating tRNA-derived fragments are decreased in patients with rheumatoid arthritis and increased in patients with psoriatic arthritis","volume":"29","author":"Dunaeva","year":"2024","journal-title":"Biomarkers"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13018-023-03843-0","article-title":"Discovery of CLEC2B as a diagnostic biomarker and screening of celastrol as a candidate drug for psoriatic arthritis through bioinformatics analysis","volume":"18","author":"Niu","year":"2023","journal-title":"J Orthop Surg Res"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2147\/CCID.S413853","article-title":"The combination of IL-6, PLR and nail psoriasis: screen for the early diagnosis of psoriatic arthritis","volume":"16","author":"Liu","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R20-20250604","first-page":"e69599","article-title":"Serum interleukin (IL)-6, lipid profile, and association with disease severity in patients with psoriasis: a cross-sectional study","volume":"16","author":"Sahoo","year":"2024","journal-title":"Cureus"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"1229516","DOI":"10.3389\/fimmu.2023.1229516","article-title":"Cytokine profile characterization of naive patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum","volume":"14","author":"Ruscitti","year":"2023","journal-title":"Front Immunol"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s40001-024-01731-9","article-title":"Serum proteome analysis identifies a potential biomarker for axial psoriatic arthritis","volume":"29","author":"Lu","year":"2024","journal-title":"Eur J Med Res"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/labmed\/lmae014","article-title":"The thiol\/disulfide balance is shifted towards oxidation in psoriatic arthritis compared to controls and is associated with higher disease activity","volume":"55","author":"Kor","year":"2024","journal-title":"Lab Med"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"109776","DOI":"10.1016\/j.jnutbio.2024.109776","article-title":"Serum selenium, selenoprotein P and glutathione peroxidase 3 in rheumatoid, psoriatic, juvenile idiopathic arthritis, and osteoarthritis","volume":"135","author":"Wahl","year":"2025","journal-title":"J Nutr Biochem"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.2174\/0109298673295359240422115759","article-title":"Does eta protein differentiate rheumatoid arthritis from psoriatic arthritis?","volume":"31","author":"Kor","year":"2024","journal-title":"Curr Med Chem"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.3390\/diagnostics13203250","article-title":"Serum and synovial levels of cathepsin G and cathepsin K in patients with psoriatic arthritis and their correlation with disease activity indices","volume":"13","author":"Popova-Belova","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"1355824","DOI":"10.3389\/fimmu.2024.1355824","article-title":"Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes","volume":"15","author":"Hammitzsch","year":"2024","journal-title":"Front Immunol"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s12325-023-02475-4","article-title":"Genetic and molecular distinctions between axial psoriatic arthritis and radiographic axial spondyloarthritis: post hoc analyses from four phase 3 clinical trials","volume":"40","author":"Kavanaugh","year":"2023","journal-title":"Adv Ther"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"e38770","DOI":"10.1097\/MD.0000000000038770","article-title":"Raftlin - a potential biomarker for axial spondyloarthritis and psoriatic arthritis: an observational study","volume":"103","author":"Yurdakul","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/rheumatology\/kead378","article-title":"Synovial and serum B cell signature of autoantibody-negative rheumatoid arthritis vs autoantibody-positive rheumatoid arthritis and psoriatic arthritis","volume":"63","author":"De Stefano","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-024-03332-7","article-title":"Investigating protease-mediated peptides of inflammation and tissue remodeling as biomarkers associated with flares in psoriatic arthritis","volume":"26","author":"Groen","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"e63857","DOI":"10.1002\/ajmg.a.63857","article-title":"Bridging the diagnostic gap for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: evidence of a common extracellular matrix fragmentation pattern in patient plasma as a potential biomarker","volume":"197","author":"Ritelli","year":"2025","journal-title":"Am J Med Genet A"},{"key":"R33-20250604","first-page":"11275","article-title":"Triglyceride glucose index: a novel biomarker in the management of patients with psoriasis","volume":"27","author":"Tamer","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2147\/CCID.S433280","article-title":"Metabolomics reveals molecular signatures for psoriasis biomarkers and drug targets discovery","volume":"16","author":"Song","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"1287637","DOI":"10.3389\/fmicb.2024.1287637","article-title":"Investigating causal associations among gut microbiota, metabolites, and psoriatic arthritis: a Mendelian randomization study","volume":"15","author":"Xu","year":"2024","journal-title":"Front Microbiol"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molimm.2023.05.010","article-title":"IL36G genetic variant is independently associated with susceptibility, severity and joint involvement in psoriasis","volume":"159","author":"Moreira","year":"2023","journal-title":"Mol Immunol"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"e003550","DOI":"10.1136\/rmdopen-2023-003550","article-title":"Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial","volume":"9","author":"Chandran","year":"2023","journal-title":"RMD Open"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdermsci.2023.07.005","article-title":"Multiomics approach identifies PI3 as a biomarker for disease severity and hyper-keratinization in psoriasis","volume":"111","author":"Deng","year":"2023","journal-title":"J Dermatol Sci"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1007\/s10067-024-07138-5","article-title":"Systematic analysis of serum peptidase inhibitor 3 in psoriasis diagnosis and treatment","volume":"43","author":"Xu","year":"2024","journal-title":"Clin Rheumatol"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.3390\/jcm12175463","article-title":"The usefulness of cellular immune inflammation markers and ultrasound evaluation in the assessment of disease activity in patients with spondyloarthritis","volume":"12","author":"Targonska-Stepniak","year":"2023","journal-title":"J Clin Med"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"e2024065","DOI":"10.5826\/dpc.1401a65","article-title":"Effect of treatment with biologic agents on the novel inflammatory biomarkers systemic immune inflammation index and systemic inflammation response index for psoriasis","volume":"14","author":"Tamer","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00403-024-02972-8","article-title":"Evaluation of the inflammatory parameters as potential biomarkers of systemic inflammation extent and the disease severity in psoriasis patients","volume":"316","author":"Zhang","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00109-023-02406-4","article-title":"A simple tool for evaluation of inflammation in psoriasis: neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as markers in psoriasis patients and related murine models of psoriasis-like skin disease","volume":"102","author":"Kommoss","year":"2024","journal-title":"J Mol Med (Berl)"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/cei\/uxae070","article-title":"Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis","volume":"218","author":"Petrovic","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"e004457","DOI":"10.1136\/rmdopen-2024-004457","article-title":"Characterisation of myeloid cells in circulation and synovial fluid of patients with psoriatic arthritis","volume":"10","author":"Fine","year":"2024","journal-title":"RMD Open"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"15299","DOI":"10.3390\/ijms242015299","article-title":"Identifying serum metabolomic markers associated with skin disease activity in patients with psoriatic arthritis","volume":"24","author":"Choksi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11306-023-02079-7","article-title":"Classifying patients with psoriatic arthritis according to their disease activity status using serum metabolites and machine learning","volume":"20","author":"Koussiouris","year":"2024","journal-title":"Metabolomics"},{"issue":"(Pt 1)","key":"R48-20250604","doi-asserted-by":"crossref","first-page":"113279","DOI":"10.1016\/j.intimp.2024.113279","article-title":"Utility of multibiomarker panel on discriminating disease activity in patients with psoriatic arthritis","volume":"143","author":"Jin","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13075-023-03125-4","article-title":"Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study","volume":"25","author":"Schett","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1007\/s10067-023-06703-8","article-title":"Is the C-reactive protein-to-albumin ratio the most remarkable simple inflammatory marker showing active disease in patients with axial spondyloarthritis, psoriatic arthritis, and rheumatoid arthritis?","volume":"42","author":"Kaplan","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/bjd\/ljad481","article-title":"The association of age at psoriasis onset and HLA-C\u221706:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"190","author":"Alabas","year":"2024","journal-title":"Br J Dermatol"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/genes14051123","article-title":"Association between IL-17F, IL-17RA gene polymorphisms and response to biological drugs in psoriasis and beyond","volume":"14","author":"Puscas","year":"2023","journal-title":"Genes (Basel)"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s13555-023-00931-1","article-title":"InflammamiR-146a and -155 plasma levels are associated with clinical efficacy of risankizumab treatment in psoriatic patients: pilot study","volume":"13","author":"Diotallevi","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"112239","DOI":"10.1016\/j.intimp.2024.112239","article-title":"Study of lncRNAs expression profile in the response to biological drugs in psoriatic arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy","volume":"134","author":"De Benedittis","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.abd.2023.03.002","article-title":"Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study","volume":"99","author":"Alves","year":"2024","journal-title":"An Bras Dermatol"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.2147\/CCID.S423234","article-title":"Effectiveness of Brodalumab in patients with moderate-to-severe plaque psoriasis located in difficult-to-treat areas","volume":"16","author":"Cacciapuoti","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/15569527.2023.2275020","article-title":"The effect of IL17 and IL23 inhibitors on hematological parameters and C-reactive protein in psoriasis patients","volume":"43","author":"Esen","year":"2024","journal-title":"Cutan Ocul Toxicol"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"e003042","DOI":"10.1136\/rmdopen-2023-003042","article-title":"Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis","volume":"9","author":"Cardner","year":"2023","journal-title":"RMD Open"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/art.42803","article-title":"Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor-inadequate responders with active psoriatic arthritis","volume":"76","author":"Siebert","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R60-20250604","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241283536","article-title":"Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2\u200ayears in participants with active psoriatic arthritis: results from a phase III randomized controlled trial","volume":"16","author":"Siebert","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R61-20250604","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3899\/jrheum.2024-0396","article-title":"Candidate biomarkers for response to treatment in psoriatic disease","volume":"51","author":"Offenheim","year":"2024","journal-title":"J Rheumatol"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00296-024-05744-9","article-title":"Microfibrillar-associated protein 4 as a predictive biomarker of treatment response in patients with chronic inflammatory diseases initiating biologics: secondary analyses based on the prospective BELIEVE cohort study","volume":"44","author":"Sofiudottir","year":"2024","journal-title":"Rheumatol Int"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.3390\/ijms25053002","article-title":"Changes in inflammatory cytokines in responders and non-responders to TNFalpha Inhibitor and IL-17A inhibitor: a study examining psoriatic arthritis patients","volume":"25","author":"Skougaard","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/art.42921","article-title":"Phase 2 trial of deucravacitinib in psoriatic arthritis: biomarkers associated with disease activity, pharmacodynamics, and clinical responses","volume":"76","author":"FitzGerald","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R65-20250604","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231192315","article-title":"Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis","volume":"15","author":"FitzGerald","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31662\/jmaj.2024-0213","article-title":"The era of preemptive medicine: developing medical digital twins through omics, IoT, and AI integration","volume":"8","author":"Ooka","year":"2025","journal-title":"JMA J"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:00:24Z","timestamp":1749013224000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001086","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}